These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22970211)

  • 1. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic.
    von Neuhoff N; Oumeraci T; Wolf T; Kollewe K; Bewerunge P; Neumann B; Brors B; Bufler J; Wurster U; Schlegelberger B; Dengler R; Zapatka M; Petri S
    PLoS One; 2012; 7(9):e44401. PubMed ID: 22970211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis.
    Barschke P; Oeckl P; Steinacker P; Ludolph A; Otto M
    Expert Rev Proteomics; 2017 Sep; 14(9):769-777. PubMed ID: 28799854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potential CSF biomarkers in ALS.
    Pasinetti GM; Ungar LH; Lange DJ; Yemul S; Deng H; Yuan X; Brown RH; Cudkowicz ME; Newhall K; Peskind E; Marcus S; Ho L
    Neurology; 2006 Apr; 66(8):1218-22. PubMed ID: 16481598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis.
    Ranganathan S; Williams E; Ganchev P; Gopalakrishnan V; Lacomis D; Urbinelli L; Newhall K; Cudkowicz ME; Brown RH; Bowser R
    J Neurochem; 2005 Dec; 95(5):1461-71. PubMed ID: 16313519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS).
    Brettschneider J; Mogel H; Lehmensiek V; Ahlert T; Süssmuth S; Ludolph AC; Tumani H
    Neurochem Res; 2008 Nov; 33(11):2358-63. PubMed ID: 18481174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis.
    Costa J; Streich L; Pinto S; Pronto-Laborinho A; Nimtz M; Conradt HS; de Carvalho M
    Mol Neurobiol; 2019 Aug; 56(8):5729-5739. PubMed ID: 30674035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Kasai T; Tokuda T; Ishigami N; Sasayama H; Foulds P; Mitchell DJ; Mann DM; Allsop D; Nakagawa M
    Acta Neuropathol; 2009 Jan; 117(1):55-62. PubMed ID: 18989684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis.
    Su XW; Simmons Z; Mitchell RM; Kong L; Stephens HE; Connor JR
    JAMA Neurol; 2013 Dec; 70(12):1505-11. PubMed ID: 24145899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS).
    Brettschneider J; Lehmensiek V; Mogel H; Pfeifle M; Dorst J; Hendrich C; Ludolph AC; Tumani H
    Neurosci Lett; 2010 Jan; 468(1):23-7. PubMed ID: 19853641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical markers in CSF of ALS patients.
    Süssmuth SD; Brettschneider J; Ludolph AC; Tumani H
    Curr Med Chem; 2008; 15(18):1788-801. PubMed ID: 18691039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis.
    Mitchell RM; Freeman WM; Randazzo WT; Stephens HE; Beard JL; Simmons Z; Connor JR
    Neurology; 2009 Jan; 72(1):14-9. PubMed ID: 18987350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis.
    Kaiserova M; Grambalova Z; Otruba P; Stejskal D; Prikrylova Vranova H; Mares J; Mensikova K; Kanovsky P
    Acta Neurol Scand; 2017 Oct; 136(4):360-364. PubMed ID: 28185258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis.
    Scarafino A; D'Errico E; Introna A; Fraddosio A; Distaso E; Tempesta I; Morea A; Mastronardi A; Leante R; Ruggieri M; Mastrapasqua M; Simone IL
    J Neurol; 2018 Oct; 265(10):2353-2362. PubMed ID: 30116940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects.
    Ranganathan S; Nicholl GC; Henry S; Lutka F; Sathanoori R; Lacomis D; Bowser R
    Amyotroph Lateral Scler; 2007 Dec; 8(6):373-9. PubMed ID: 17852009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients.
    Benigni M; Ricci C; Jones AR; Giannini F; Al-Chalabi A; Battistini S
    Neuromolecular Med; 2016 Dec; 18(4):551-560. PubMed ID: 27119371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
    Ekegren T; Hanrieder J; Bergquist J
    J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF chitinase proteins in amyotrophic lateral sclerosis.
    Thompson AG; Gray E; Bampton A; Raciborska D; Talbot K; Turner MR
    J Neurol Neurosurg Psychiatry; 2019 Nov; 90(11):1215-1220. PubMed ID: 31123140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroproteomics: an insight into ALS.
    Mendonça DM; Pizzati L; Mostacada K; de S Martins SC; Higashi R; Ayres Sá L; Moura Neto V; Chimelli L; Martinez AM
    Neurol Res; 2012 Dec; 34(10):937-43. PubMed ID: 23146297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects.
    Wuolikainen A; Jonsson P; Ahnlund M; Antti H; Marklund SL; Moritz T; Forsgren L; Andersen PM; Trupp M
    Mol Biosyst; 2016 Apr; 12(4):1287-98. PubMed ID: 26883206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.